

ForPatients

by Roche

Lymphoma

A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Trial Status

Not Yet Recruiting

Trial Runs In

1 Countries

Trial Identifier

NCT06624085 GO44900

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

The purpose of the study is to evaluate glofitamab + gemcitabine + oxaliplatin in participants in the United States, including under-represented racial and ethnic populations, that have relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

Hoffmann-La Roche

Sponsor

Phase 1

Phase

NCT06624085 GO44900

Trial Identifiers

Eligibility Criteria:

Gender

All

Age

>=18 Years

Healthy Volunteers

No
